Salim Syed discusses this morning’s FOREST-HCM update, Gilead’s Trodelvy news, CRISPR’s allo CAR-T pivot, BridgeBio’s possible reaction to HELIOS-B, and Vaxcyte’s pneumococcal vaccine readout coming up later this year.
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
.png){kind=logo}
